Celebrating its 30th anniversary, the European Hematology Association’s EHA2022 Congress in Vienna brought together global research leaders, practitioners and other participants to share the latest advances in hematology. The hybrid event was June 9-12, with access to a virtual platform through August 15, 2023, where abstracts will be available. A few MPN highlights follow.
How to select patients with myelofibrosis for transplantation and how to manage MF patients during a transplant procedure.
Jean Jacques Kiladjian, Pr, MD, PhD, Hospital Saint-Louis and INSERM, Paris.
Pegylated interferon-alfa found to control the differentiation of blood stem cells in MPNs, which could lead to new treatments to stop this process.
Related abstract: 57 Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR-mutated Essential Thrombocythemia (ET) Patients.
Anna S Nam, MD, Weill Cornell Medicine, New York
National quality of life survey across MPNs shows areas of patient/physician relationship needed improvement.
Related abstract: Health-Related Quality of Life in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Nationwide Population-Based Survey in Denmark.
Tatiana Ianova, Multinational Center for Quality of Life Research, St. Petersburg
Evaluation of the prognostic value of thrombophilia markers in patients with MPNs shows how some predictive biomarkers could be helpful to understand and inhibit MPN progression.
Abstract not yet available. Tatyana Makarik, National Research Center for Hematology, Moscow
Mutational studies elucidate differences and intersections of MPNs and myelodysplastic syndrome (MDS), which could lead to more accurate diagnosis and choice of treatment for these patients.
Alejandro Pita, MD, Hepatobiliary Surgery, Transplantation, University Hospital of Salamanca, Spain